Insmed (INSM) Projected to Post Earnings on Thursday

Key Points

• Insmed is set to report its Q2 2025 earnings on August 7th, with analysts predicting a loss of ($1.31) per share and revenue of $104.06 million.
• The company previously reported a loss of ($1.42) per share in its last quarterly earnings, falling short of estimates, but with revenue increasing by 22.9% year-over-year to $92.82 million.
• Insmed's stock has received multiple "buy" ratings from analysts, with price targets ranging from $109 to $130, while insiders have sold a significant amount of shares recently.

Insmed (NASDAQ:INSM - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Insmed to post earnings of ($1.31) per share and revenue of $104.06 million for the quarter. Insmed has set its FY 2025 guidance at EPS.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative return on equity of 446.98% and a negative net margin of 265.93%. The business had revenue of $92.82 million during the quarter, compared to analysts' expectations of $91.63 million. During the same period last year, the company earned ($1.06) earnings per share. The firm's revenue was up 22.9% compared to the same quarter last year. On average, analysts expect Insmed to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Insmed Stock Up 1.3%

NASDAQ:INSM traded up $1.41 during mid-day trading on Friday, reaching $108.69. The company's stock had a trading volume of 2,256,053 shares, compared to its average volume of 2,331,694. Insmed has a 1 year low of $60.40 and a 1 year high of $108.89. The stock has a fifty day moving average of $94.41 and a 200-day moving average of $81.12. The firm has a market capitalization of $20.62 billion, a PE ratio of -18.27 and a beta of 0.95. The company has a quick ratio of 5.44, a current ratio of 5.86 and a debt-to-equity ratio of 11.38.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Citigroup raised shares of Insmed to a "buy" rating in a research note on Tuesday, June 10th. HC Wainwright increased their price target on shares of Insmed from $90.00 to $120.00 and gave the company a "buy" rating in a research report on Wednesday, June 11th. Morgan Stanley increased their price target on shares of Insmed from $102.00 to $108.00 and gave the company an "overweight" rating in a research report on Thursday, July 17th. Royal Bank Of Canada increased their price target on shares of Insmed from $99.00 to $106.00 and gave the company an "outperform" rating in a research report on Wednesday, June 11th. Finally, Leerink Partners increased their price target on shares of Insmed from $100.00 to $115.00 and gave the company an "outperform" rating in a research report on Tuesday, June 10th. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $109.20.

Insider Buying and Selling at Insmed

In related news, CEO William Lewis sold 129,805 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $100.39, for a total value of $13,031,123.95. Following the transaction, the chief executive officer owned 233,924 shares in the company, valued at approximately $23,483,630.36. This represents a 35.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Sara Bonstein sold 58,400 shares of the firm's stock in a transaction that occurred on Monday, July 21st. The stock was sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the sale, the chief financial officer directly owned 73,505 shares in the company, valued at $7,546,758.35. The trade was a 44.27% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 599,767 shares of company stock worth $54,625,108 in the last 90 days. Corporate insiders own 3.00% of the company's stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.